Brief: Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial Of Bx1000
25/04/2023 13:50
Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES POSITIVE TOP-LINE FINAL RESULTS FROM
PHASE
2 RANDOMIZED CLINICAL TRIAL OF BX1000
* BAUDAX BIO INC - BX1000 MET PRIMARY ENDPOINT
* BAUDAX BIO INC - ALL PATIENTS IN THREE BX1000 TREATMENT
COHORTS
MET CRITERIA FOR GOOD OR EXCELLENT INTUBATION CONDITIONS AT 60
SECONDS
* BAUDAX BIO - WILL BE CONTINUING DEVELOPMENT PROGRAM FOR BX
1000
WITH A TARGET OF SUBMITTING A NEW DRUG APPLICATION BY ABOUT
YEAR-END 2025
Source text for Eikon: ID:nGNX4fwNNf
Further company coverage: BXRX.O
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer